Role of mTOR Signaling in Tumor Microenvironment: An Overview

Citations Over TimeTop 10% of 2018 papers

Abstract

The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME). In recent years, it has been well recognized that cancer cells co-exist and co-evolve with their TME, which is often involved in drug resistance. The mTOR pathway modulates the interactions between the stroma and the tumor, thereby affecting both the tumor immunity and angiogenesis. The activation of mTOR signaling is associated with these pro-oncogenic cellular processes, making mTOR a promising target for new combination therapies. This review highlights the role of mTOR signaling in the characterization and the activity of the TME's elements and their implications in cancer immunotherapy.

Related Papers

• → Targeting mTOR globally in cancer: Thinking beyond rapamycin(2009)155 cited
• → Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells(2006)148 cited
• → Cancer cells dysregulate PI3K/AKT/mTOR pathway activation to ensure their survival and proliferation: mimicking them is a smart strategy of gammaherpesviruses(2021)37 cited
• → Adaptation to chronic mTOR inhibition in cancer and in aging(2013)13 cited
• → Abstract A49: Transcription factor upregulation after mTOR inhibition by Torin1 induces growth factor receptor expression(2017)